Prevacid patent upheld

Share this article:
A federal judge has upheld a Takeda Pharmaceutical and Abbott Laboratories patent for the drugmakers' jointly marketed heartburn drug Prevacid.

The ruling "will ease investor concerns regarding the pending split of the TAP joint venture between Abbott and Takeda," analyst Lawrence Keusch of Goldman Sachs said in an investor note. “The ruling should also keep generic competition at bay and allow Abbott to collect royalties on an intact Prevacid franchise prior to the patent expiration in 2009.”

US District Judge Sue Robinson, in Wilmington, Delaware, ruled a patent on Prevcid is both valid and enforceable.

Generics drugmaker Teva, which sought to market a copycat version of the drug, has pledged to appeal.

Prevacid is made by TAP Pharmaceutical Products, a joint-venture between Takeda and Abbott.  Last month, the companies agreed to split the venture, with Takeda getting Prevacid. Analysts said in published reports that the court decision will ensure that agreement goes as planned since a loss would have required a renegotiation between Abbott and Takeda.
Share this article:

Email Newsletters

More in News

Five things for pharma marketers to know: Friday, August 22

Five things for pharma marketers to know: Friday, ...

Two new indications give Eliquis more juice, a new rule is making hydrocodone harder to get and the ALS Ice Bucket Challenge highlights a controversial aspects of drug discovery and ...

Lilly takes on Amgen's Enbrel

Lilly takes on Amgen's Enbrel

Phase-III tests indicate Lilly's experimental treatment bests Amgen's for moderate-to-severe plaque psoriasis.

GSK Ellipta franchise expands

GSK Ellipta franchise expands

The FDA has approved Arnuity Ellipta for asthma.